2022.05.05
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act
I-Mab today provided updates on its status under the Holding Foreign Companies Accountable Act.
2022.04.28
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
I-Mab announced today two key appointments of Mr. Richard Yeh as Chief Operating Officer and Dr. John Hayslip as Chief Medical Officer.
2022.03.31
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
I-Mab today announced that the Company’s key shareholders and its senior management team have voluntarily entered into a 180-days lock-up period commencing from March 31, 2022.
2022.03.29
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
I-Mab today announced financial results for the 12 months ended December 31, 2021, and provided key business updates.
2022.03.18
I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022
I-Mab today announced that the Company will report financial results for the full year ended December 31, 2021 before the market opens on Tuesday, March 29, 2022.
2022.03.15
I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act
I-Mab today provides updates on the recent development relating to the HFCAA and its implementation.
2022.03.09
I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
I-Mab today announced that two poster presentations featuring translational research data of enoblituzumab and preclinical data of TJ-C64B will be presented at AACR 2022.
2022.03.03
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer
I-Mab today announced that the U.S. FDA has granted Orphan Drug Designation for TJ-CD4B for the treatment of gastric cancer including cancer of gastroesophageal junction.
2022.01.28
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
I-Mab announced the signing of a partnership agreement with the Hangzhou Qiantang New Area in China to manufacture its innovative drugs locally and accelerate its transition to commercialization.
2022.01.18
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
I-Mab today announced that the first patient has been dosed in its China phase 2 trial of lemzoparlimab in combination with the PD-1 antibody toripalimab in patients with advanced solid tumors.